2024-09-25 – Health – www.prnewswire.com
Adults aged 60 and over with underlying co-morbidities are at high risk of developing severe infections from RSV Vaccine showed 82.6% overall vaccine efficacy against RSV-LRTD with 94.6% efficacy observed in adults with co-morbidities vii KUALA LUMPUR, Malaysia, Sept. 25, 2024…